Skip to main content
. 2015 Oct 19;6(40):42632–42650. doi: 10.18632/oncotarget.5822

Figure 6. ACSL4 effects on the mTOR pathway in MDA-MB-231 cells.

Figure 6

MDA-MB-231 cells were transfected with the pSUPER.retro plasmid containing a shRNA targeted to ACSL4 (shRNA-ACSL4) or an empty plasmid (mock). Forty-eight hours post transfection, cells were selected with puromycin (1 μg/ml) antibiotic. One month post selection, whole cell extracts were obtained and analyzed by Western blot as previously described using the indicated antibodies. Representative blots A. and integrated optical density of protein levels B. quantified and normalized with the corresponding β-tubulin signal. Data represent the means of fold changes (shRNA-ACSL4 vs. mock) ± SD of three independent experiments. Dotted line indicates control values. a, b, c, d, f and g: ***p < 0.001; e: **p < 0.01 vs. mock transfected cells.